TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6247521

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy alone
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy and radiotherapy (including prophylactic brain irradiation in four patients)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 337
Study: 31950855

Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 36
Study: 29084407

Group type: EXPERIMENTAL
Intervention: Daytime (9 a.m. to 5 p.m.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nighttime (9 p.m. to 5 a.m.)
Number of subjects: 24
Study: 28356133

Group type: EXPERIMENTAL
Intervention: Abdominal massage once daily for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No massage (control group)
Number of subjects: 0
Study: 26240207

Group type: EXPERIMENTAL
Intervention: GARDASIL 9 (9‐valent human papillomavirus [9vHPV] vaccine) administered concomitantly with MCV4/Tdap
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: MCV4/Tdap administered concomitantly with 9vHPV vaccine
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Tdap administered concomitantly with 9vHPV vaccine
Number of subjects: 1241
Study: 23207893

Group type: EXPERIMENTAL
Intervention: Proprioceptive exercise session using a BOSU ball and a Swiss ball as unstable platforms (six 25-minute sessions).
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no additional proprioceptive training, only warm-up).
Number of subjects: 37
Study: 21931078

Group type: EXPERIMENTAL
Intervention: Access arm with audible alerts for threshold crossings
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control arm without audible alerts
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Access arm
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 335
Study: 18241708

Group type: EXPERIMENTAL
Intervention: Propofol-based anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desflurane-based anesthesia
Number of subjects: 60
Study: 15910632

Group type: EXPERIMENTAL
Intervention: AA genotype of the MspI polymorphism of Apo AI
Number of subjects: 1224
Study: 12637608

Group type: EXPERIMENTAL
Intervention: TNX‐901 (450 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TNX‐901 (300 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TNX‐901 (150 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 10680434

Group type: EXPERIMENTAL
Intervention: Itraconazole solution 800 mg day‐1
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Itraconazole solution 400 mg day‐1 (s/c1200)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Itraconazole solution 400 mg day‐1 with loading dose of 800 mg day‐1 capsules for 7 days
Number of subjects: 123

Group type: COMPARATOR
Intervention: Itraconazole solution 400 mg day‐1
Number of subjects: 123

Group type: COMPARATOR
Intervention: Itraconazole capsules 400, 600 or 800 mg day‐1
Number of subjects: 123
Study: 8619361

Group type: EXPERIMENTAL
Intervention: Iobitridol (250-300 mg)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Iopromide (control for i.v. DSA)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Iohexol (control for i.a. DSA)
Number of subjects: 139
Study: 1768321

Group type: EXPERIMENTAL
Intervention: Recurrent abortion history (short vs long)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Maternal age (over 30 years)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Abortion x years index
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Subfertility problems
Number of subjects: 165
Study: 7256696

Group type: EXPERIMENTAL
Intervention: Aspirin (0.6 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipyridamole (150 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31385041

Group type: EXPERIMENTAL
Intervention: Enoxaparin (20 mg, twice daily), started 24-36 hours after surgery and continued until discharge
Number of subjects: 121

Group type: COMPARATOR
Intervention: IPC alone
Number of subjects: 121
Study: 31084573

Group type: EXPERIMENTAL
Intervention: Dyad group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Large group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Delayed control group
Number of subjects: 48
Study: 28596236

Group type: EXPERIMENTAL
Intervention: hyperinsulinemic hypoglycemia (bolus insulin)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: hyperinsulinemic euglycemia (bolus insulin and glucose infusion)
Number of subjects: 9

Group type: COMPARATOR
Intervention: saline control
Number of subjects: 9
Study: 26530312

Group type: EXPERIMENTAL
Intervention: Low-FODMAP EN
Number of subjects: 100

Group type: COMPARATOR
Intervention: Moderate-FODMAP EN
Number of subjects: 100

Group type: COMPARATOR
Intervention: High-FODMAP EN
Number of subjects: 100

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diarrhea improved group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Recurrent diarrhea/constipation improved group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diarrhea-improved and recurrent diarrhea/constipation groups
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Constipation-improved group
Number of subjects: 100
Study: 25651741

Group type: EXPERIMENTAL
Intervention: Isotonic exercise (cycloergometer)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Isometric exercise (handgrip)
Number of subjects: 87
Study: 21114411

Group type: EXPERIMENTAL
Intervention: Intraurethral alprostadil 125 to 250 μg daily for 9 months
Number of subjects: 127

Group type: COMPARATOR
Intervention: Oral sildenafil citrate 50 mg daily for 9 months
Number of subjects: 127
Study: 19651563

Group type: COMPARATOR
Intervention: Lactobacillus acidophilus NCFM (N = 110)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Lactobacillus acidophilus NCFM + Bifidobacterium animalis subsp lactis Bi‐07 (N = 112)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Placebo (N = 104)
Number of subjects: 326
Study: 17969892

Group type: EXPERIMENTAL
Intervention: Entropy-based complex systems partition method (EBCSPM)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 403
Study: 15375810

Group type: EXPERIMENTAL
Intervention: Forced-use therapy (FUT) - wearing a thick constraint mitten on the sound arm for as many as 6 hours a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 11451210

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 10-80 mg
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 2.5-40 mg
Number of subjects: 792
Study: 9848557

Group type: EXPERIMENTAL
Intervention: Kessler repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robertson repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Locking Strickland repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified Becker repair
Number of subjects: 0
Study: 7532497

Group type: EXPERIMENTAL
Intervention: Remantadine (1.5 mg/kg body weight, 3 times a day for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 2527538

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1071671

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (1-5-2-0 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 mg of propranolol
Number of subjects: 20
Study: 31121015

Group type: EXPERIMENTAL
Intervention: Doravirine (DOR) with lamivudine (3TC)/tenofovir disoproxil fumarate (TDF) or DOR (100 mg QD) with emtricitabine (FTC)/TDF or abacavir (ABC)/3TC
Number of subjects: 747

Group type: COMPARATOR
Intervention: Darunavir plus ritonavir (DRV+r) (800/100 mg QD) with FTC/TDF or ABC/3TC
Number of subjects: 747

Group type: COMPARATOR
Intervention: Efavirenz (EFV) with FTC/TDF (600/200/300 mg QD)
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Doravirine (DOR)
Number of subjects: 747

Group type: COMPARATOR
Intervention: Darunavir plus ritonavir (DRV+r)
Number of subjects: 747

Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 747
Study: 28571997

Group type: EXPERIMENTAL
Intervention: Telephone-based patient-centered intervention delivered by a pharmacist, integrating brief negotiated interviewing and shared decision-making.
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1400
Study: 25621378

Group type: EXPERIMENTAL
Intervention: Horizontal eye movements
Number of subjects: 0
Study: 25069344

Group type: EXPERIMENTAL
Intervention: Extraoral ABS
Number of subjects: 55

Group type: COMPARATOR
Intervention: Traditional intraoral ABS
Number of subjects: 55
Study: 21669162

Group type: EXPERIMENTAL
Intervention: Arsenicum Album LM 0/3 (verum)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 19760283

Group type: EXPERIMENTAL
Intervention: Caffeine (280 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Caffeine (0 mg, placebo)
Number of subjects: 60
Study: 17138082

Group type: COMPARATOR
Intervention: Landiolol 0 mg/kg (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Landiolol 0.1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Landiolol 0.2 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Landiolol 0.3 mg/kg
Number of subjects: 0
Study: 12921224

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11266482

Group type: EXPERIMENTAL
Intervention: Surgical curettage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (HIV- patients as control)
Number of subjects: 0
Study: 8940230

Group type: EXPERIMENTAL
Intervention: Combined PRP‐T/DTP vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTP vaccine only
Number of subjects: 0
Study: 1416161

Group type: EXPERIMENTAL
Intervention: GTN (glyceryl trinitrate) infusion at 0.5 micrograms.kg‐1.min‐1
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Stepwise increasing infusion of GTN
Number of subjects: 53
Study: 2860284

Group type: EXPERIMENTAL
Intervention: Mérieux human diploid-cell-strain vaccine (HDCSV), 0.1 ml intradermally, at eight sites on day 0, at four sites on day 7, and at one site on days 28 and 91
Number of subjects: 155

Group type: COMPARATOR
Intervention: Semple vaccine (SV)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Equine anti-rabies serum (EARS), 80 IU/kg on day 0
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Mérieux human diploid-cell-strain vaccine (HDCSV)
Number of subjects: 155
Study: 29560777

Group type: EXPERIMENTAL
Intervention: Outreach Visits (OV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 100
Study: 26841216

Group type: EXPERIMENTAL
Intervention: Lifestyle Advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study: 24650810

Group type: EXPERIMENTAL
Intervention: Take Home Naloxone (THN) kits distributed by trained paramedics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up rates for patients consented and completed questionnaires (postal or telephone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative data about acceptability to patients and paramedics through interviews and focus groups
Number of subjects: 0
Study: 22900984

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (GS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 19841161

Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg bid alone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Lacosamide 200 mg bid with carbamazepine 200 mg bid
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Carbamazepine 200 mg bid alone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Carbamazepine 200 mg bid with lacosamide 200 mg bid
Number of subjects: 37
Study: 18543427

Group type: EXPERIMENTAL
Intervention: HyperHaes (combined hypertonic colloidal solution)
Number of subjects: 0
Study: 15682287

Group type: EXPERIMENTAL
Intervention: Automated CMR planning derived from gated scouts in free-breathing mode
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Automated CMR planning derived from gated scouts in breath-holding mode
Number of subjects: 10

Group type: COMPARATOR
Intervention: Manual CMR planning
Number of subjects: 10
Study: 12173835

Group type: COMPARATOR
Intervention: Medtronic Octopus 3
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Genzyme Immobilizer
Number of subjects: 100
Study: 10468701

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8713219

Group type: EXPERIMENTAL
Intervention: Zinc sulphate capsules, 220 mg three times a day
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 2105070

Group type: EXPERIMENTAL
Intervention: Target PaCO2 of 40 mmHg, measured at 37 degrees C
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Target PaCO2 corrected to patient's rectal temperature (mean 30.1, SD 1.9 degrees C)
Number of subjects: 86
Study: 417372

Group type: EXPERIMENTAL
Intervention: d-amphetamine at three dose levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0
Study: 6805841

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulphate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 50
Study: 30866922

Group type: EXPERIMENTAL
Intervention: Task trainer (Life/form®, Fort Atkinson WI)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Instructional video
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Peer practice
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 150
Study: 29465559

Group type: EXPERIMENTAL
Intervention: Rehabilitation group
Number of subjects: 130
Study: 26858279

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Aerobic Continuous Training (ACT)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both AIT and ACT
Number of subjects: 163
Study: 24644095

Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat 800/150 mg (FDC G003)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat 800/150 mg (FDC G004)
Number of subjects: 36

Group type: COMPARATOR
Intervention: darunavir 800 mg and ritonavir 100 mg (single agents)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat (FDCs)
Number of subjects: 36
Study: 22843789

Group type: EXPERIMENTAL
Intervention: Paclitaxel therapy
Number of subjects: 855
Study: 19597418

Group type: EXPERIMENTAL
Intervention: Exercise therapy (specific programme of exercise therapy twice a day throughout the entire hospitalization phase)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard mobilization programme (control group)
Number of subjects: 64
Study: 17545373

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination at one fifth of a standard dose
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard intramuscular vaccination
Number of subjects: 112
Study: 16287454

Group type: EXPERIMENTAL
Intervention: Sildenafil (25- or 50-mg, titrated to 100-mg)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Tadalafil (10-mg, titrated to 20-mg)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 367
Study: 12221405

Group type: EXPERIMENTAL
Intervention: Pulsed Doppler tissue imaging (DTI) in BMD patients (A1: LVEF >= 55%, n=20; A2: LVEF < 55%, n=8)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pulsed Doppler tissue imaging (DTI) in BMD patients (A1, A2) and carriers
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pulsed Doppler tissue imaging (DTI) in A2 and carriers
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pulsed Doppler tissue imaging (DTI) in A1, A2, and carriers
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pulsed Doppler tissue imaging (DTI)
Number of subjects: 66
Study: 9620192

Group type: EXPERIMENTAL
Intervention: Continuous passive motion
Number of subjects: 25

Group type: COMPARATOR
Intervention: Modified Madden protocol
Number of subjects: 25
Study: 7632427

Group type: EXPERIMENTAL
Intervention: Medical examination of adults with mental retardation
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Medical disorders prevalence
Number of subjects: 202
Study: 2653895

Group type: EXPERIMENTAL
Intervention: medium absorbant tampons
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: super‐absorbant tampons
Number of subjects: 17

Group type: COMPARATOR
Intervention: control (not specified)
Number of subjects: 17
Study: 216094

Group type: EXPERIMENTAL
Intervention: letosteine (50 mg t.i.d.)
Number of subjects: 47

Group type: COMPARATOR
Intervention: S‐carboxy‐methyl‐cysteine (750 mg t.i.d.)
Number of subjects: 47
Study: 31443727

Group type: EXPERIMENTAL
Intervention: NMES + FES
Number of subjects: 48

Group type: COMPARATOR
Intervention: Passive + FES (control)
Number of subjects: 48
Study: 27473629

Group type: EXPERIMENTAL
Intervention: IV and perineural dexamethasone (1 ml of a 4 mg/ml dexamethasone solution)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IV dexamethasone alone (8 mg)
Number of subjects: 40
Study: 26555779

Group type: EXPERIMENTAL
Intervention: ePAQ-PF (completed prior to visit)
Number of subjects: 284
Study: 23600609

Group type: EXPERIMENTAL
Intervention: RMT at 55% of maximal inspiratory effort (EXP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group at 10% of maximal inspiratory effort (CON)
Number of subjects: 36
Study: 21690303

Group type: EXPERIMENTAL
Intervention: Drug facts format
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional format
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Q&A format
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Highlights format
Number of subjects: 300
Study: 19809205

Group type: EXPERIMENTAL
Intervention: Nifedipine controlled release (CR) 25 mg/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nifedipine and Amlodipine
Number of subjects: 26
Study: 17536870

Group type: EXPERIMENTAL
Intervention: Bramitob (300mg nebulized dose)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Tobi (300mg nebulized dose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bramitob
Number of subjects: 11

Group type: COMPARATOR
Intervention: Tobi
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bramitob and Tobi
Number of subjects: 11
Study: 15297201

Group type: EXPERIMENTAL
Intervention: Platinum-based therapy
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Combination platinum/paclitaxel therapy
Number of subjects: 1759
Study: 11030497

Group type: EXPERIMENTAL
Intervention: TBI-MET group (those who met learning criterion)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TBI-NOT MET group (those who did not meet learning criterion)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TBI-MET group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: TBI-NOT MET group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All groups (TBI-MET, TBI-NOT MET, HCs)
Number of subjects: 28
Study: 9211021

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 7788

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7788
Study: 8439017

Group type: EXPERIMENTAL
Intervention: 2 mg intravenous midazolam
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 48
Study: 3752417

Group type: EXPERIMENTAL
Intervention: Budesonide aerosol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 0
Study: 31221679

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion threshold (transfuse if hemoglobin<7.5 g/dl)
Number of subjects: 4531

Group type: COMPARATOR
Intervention: Liberal transfusion threshold (transfuse if hemoglobin<9.5 g/dl in the operating room or ICU, or if hemoglobin<8.5 g/dl on the non-ICU ward)
Number of subjects: 4531

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion threshold (transfuse if hemoglobin<7.5 g/dl) among patients with preoperative CKD
Number of subjects: 4531

Group type: COMPARATOR
Intervention: Liberal transfusion threshold (transfuse if hemoglobin<9.5 g/dl in the operating room or ICU, or if hemoglobin<8.5 g/dl on the non-ICU ward) among patients with preoperative CKD
Number of subjects: 4531
Study: 27514371

Group type: EXPERIMENTAL
Intervention: Combination therapy of solifenacin 5/10 mg + mirabegron 25/50 mg
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: Combination therapy of solifenacin 10 mg + mirabegron 25 mg
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: Combination therapy of solifenacin 5 mg + mirabegron 50 mg
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 1278
Study: 25740286

Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy (administered intravenously every 2 weeks with pegfilgrastim support) with fluorouracil plus EC-P (FEC-P)
Number of subjects: 2091

Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy (administered intravenously every 2 weeks with pegfilgrastim support) with EC-P
Number of subjects: 2091

Group type: COMPARATOR
Intervention: Standard-interval chemotherapy (administered intravenously every 3 weeks) with FEC-P
Number of subjects: 2091

Group type: COMPARATOR
Intervention: Standard-interval chemotherapy (administered intravenously every 3 weeks) with EC-P
Number of subjects: 2091

Group type: COMPARATOR
Intervention: Dose-dense chemotherapy (every 2 weeks)
Number of subjects: 2091

Group type: EXPERIMENTAL
Intervention: Addition of fluorouracil to chemotherapy
Number of subjects: 2091